The FDA's decision to accept a new drug application (NDA) for pitolisant, a medicine Harmony Biosciences LLC is advancing following the drug's 2016 EMA approval, throws open the door that 2019 could bring U.S. narcolepsy patients two new medicines for excessive daytime sleepiness (EDS). An FDA decision on Jazz Pharmaceuticals plc's solriamfetol filing, the other NDA in review, is expected by March 20. Both drugs will face competition from wake-promoting agents, such as modafinil and armodafinil, and generic stimulants.